Pharmacogenomics of cardiovascular drugs

Cardiovascular pharmacogenomics.

There is large interpatient variability in the response to drugs, including cardiovascular drugs. Thus, while some patients achieve the desired therapeutic response from their drug therapy, others do not. There is also a subset of patients who will experience adverse effects, which can range from bothersome to life threatening. Research in recent years has provided compelling evidence that in m...

Applied pharmacogenomics in cardiovascular medicine.

Interindividual heterogeneity in drug response is a central feature of all drug therapies. Studies in individual patients, families, and populations over the past several decades have identified variants in genes encoding drug elimination or drug target pathways that in some cases contribute substantially to variable efficacy and toxicity. Important associations of pharmacogenomics in cardiovas...

Pharmacogenomics of cardiovascular pharmacology: pharmacogenomic network of cardiovascular disease models.

The most important strategies in pharmacogenomics are gene expression profiling and the network analysis of human disease models. We have previously discovered novel drug target candidates in cardiovascular diseases through investigations of these pharmacogenomics. The significant induction of S100C mRNA and protein expression was detected in the rat pulmonary hypertension and myocardial infarc...

Poisonings by Cardiovascular Drugs in Yekaterinburg, Russia

Background: The pattern of poisoning in Russia may be different from other countries. The study objective was to describe the pattern of poisoning with cardiovascular drugs in a major industrial city in Russia, Yekaterinburg. Methods: This study was part of a larger prospective multi-center study including all acute poisonings in patients older than 15 years of age in the city of Yekaterinburg...

Drug Interactions, Pharmacogenomics and Cardiovascular Complication